Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program
CLRB•Corporate presentation highlights iopofosine I-131 program and platform updates
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program
- Cellectar outlined a Phase 3 confirmatory study for iopofosine I-131 in Waldenström macroglobulinemia, targeting first patient enrolled in 1Q27.
- Accelerated approval filing targeted for 1H27 using Phase 2b CLOVER-WaM data with Phase 3 initiation and progress.
- Phase 2b CLOVER-WaM showed statistically significant primary endpoint; evaluable population ORR 83.6%, MRR 61.8%, DCR 98.2%, VGPR/CR 14.5%.
- Median duration of response 533 days (17.8 months); median progression-free survival 406 days (13.5 months) at December 2025 cutoff.
- Presentation also highlighted PDC platform expansion, including CLR 125 in Phase 1b/2 TNBC and CLR 225 Actinium-225 pancreatic program listed as Phase 1a/b ready.
